These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 26483423)

  • 1. Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer.
    Kroon J; Puhr M; Buijs JT; van der Horst G; Hemmer DM; Marijt KA; Hwang MS; Masood M; Grimm S; Storm G; Metselaar JM; Meijer OC; Culig Z; van der Pluijm G
    Endocr Relat Cancer; 2016 Jan; 23(1):35-45. PubMed ID: 26483423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucocorticoid Receptor and β-Catenin Interact in Prostate Cancer Cells and Their Co-Inhibition Attenuates Tumorsphere Formation, Stemness, and Docetaxel Resistance.
    Martinez SR; Elix CC; Ochoa PT; Sanchez-Hernandez ES; Alkashgari HR; Ortiz-Hernandez GL; Zhang L; Casiano CA
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy.
    Puhr M; Hoefer J; Eigentler A; Ploner C; Handle F; Schaefer G; Kroon J; Leo A; Heidegger I; Eder I; Culig Z; Van der Pluijm G; Klocker H
    Clin Cancer Res; 2018 Feb; 24(4):927-938. PubMed ID: 29158269
    [No Abstract]   [Full Text] [Related]  

  • 4. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer.
    Isikbay M; Otto K; Kregel S; Kach J; Cai Y; Vander Griend DJ; Conzen SD; Szmulewitz RZ
    Horm Cancer; 2014 Apr; 5(2):72-89. PubMed ID: 24615402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential targeting of androgen and glucocorticoid receptors induces ER stress and apoptosis in prostate cancer cells: a novel therapeutic modality.
    Yemelyanov A; Bhalla P; Yang X; Ugolkov A; Iwadate K; Karseladze A; Budunova I
    Cell Cycle; 2012 Jan; 11(2):395-406. PubMed ID: 22223138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucocorticoid Receptor Regulates and Interacts with LEDGF/p75 to Promote Docetaxel Resistance in Prostate Cancer Cells.
    Sanchez-Hernandez ES; Ochoa PT; Suzuki T; Ortiz-Hernandez GL; Unternaehrer JJ; Alkashgari HR; Diaz Osterman CJ; Martinez SR; Chen Z; Kremsky I; Wang C; Casiano CA
    Cells; 2023 Aug; 12(16):. PubMed ID: 37626856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Dual Androgen Receptor and Glucocorticoid Receptor Antagonist CB-03-10 as Potential Treatment for Tumors that have Acquired GR-mediated Resistance to AR Blockade.
    Rosette C; Agan FJ; Rosette N; Mazzetti A; Moro L; Gerloni M
    Mol Cancer Ther; 2020 Nov; 19(11):2256-2266. PubMed ID: 32847976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer.
    Lin JZ; Wang ZJ; De W; Zheng M; Xu WZ; Wu HF; Armstrong A; Zhu JG
    Oncotarget; 2017 Jun; 8(25):41064-41077. PubMed ID: 28455956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
    Li X; Wu JB; Chung LW; Huang WC
    Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Prostate Cancer Cells Resistant to Docetaxel as in vitro Model for Discovering MicroRNAs Predictive of the Onset of Docetaxel Resistance.
    Bascetta L; Oliviero A; D'Aurizio R; Evangelista M; Mercatanti A; Pellegrini M; Marrocolo F; Bracarda S; Rizzo M
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28703747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucocorticoids Induce Stress Oncoproteins Associated with Therapy-Resistance in African American and European American Prostate Cancer Cells.
    Woods-Burnham L; Cajigas-Du Ross CK; Love A; Basu A; Sanchez-Hernandez ES; Martinez SR; Ortiz-Hernández GL; Stiel L; Durán AM; Wilson C; Montgomery S; Roy S; Casiano CA
    Sci Rep; 2018 Oct; 8(1):15063. PubMed ID: 30305646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid Receptor.
    Adelaiye-Ogala R; Gryder BE; Nguyen YTM; Alilin AN; Grayson AR; Bajwa W; Jansson KH; Beshiri ML; Agarwal S; Rodriguez-Nieves JA; Capaldo B; Kelly K; VanderWeele DJ
    Mol Cancer Ther; 2020 Jul; 19(7):1436-1447. PubMed ID: 32371590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The stem cell inhibitor salinomycin decreases colony formation potential and tumor-initiating population in docetaxel-sensitive and docetaxel-resistant prostate cancer cells.
    Gruber M; Handle F; Culig Z
    Prostate; 2020 Feb; 80(3):267-273. PubMed ID: 31834633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PrLZ increases prostate cancer docetaxel resistance by inhibiting LKB1/AMPK-mediated autophagy.
    Zeng J; Liu W; Fan YZ; He DL; Li L
    Theranostics; 2018; 8(1):109-123. PubMed ID: 29290796
    [No Abstract]   [Full Text] [Related]  

  • 15. MicroRNA-223-3p regulates cell chemo-sensitivity by targeting FOXO3 in prostatic cancer.
    Feng Q; He P; Wang Y
    Gene; 2018 Jun; 658():152-158. PubMed ID: 29518547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor.
    Shiota M; Kashiwagi E; Yokomizo A; Takeuchi A; Dejima T; Song Y; Tatsugami K; Inokuchi J; Uchiumi T; Naito S
    Prostate; 2013 Sep; 73(12):1336-44. PubMed ID: 23775496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-27b and miR-34a enhance docetaxel sensitivity of prostate cancer cells through inhibiting epithelial-to-mesenchymal transition by targeting ZEB1.
    Zhang G; Tian X; Li Y; Wang Z; Li X; Zhu C
    Biomed Pharmacother; 2018 Jan; 97():736-744. PubMed ID: 29102917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors.
    Xie N; Cheng H; Lin D; Liu L; Yang O; Jia L; Fazli L; Gleave ME; Wang Y; Rennie P; Dong X
    Int J Cancer; 2015 Feb; 136(4):E27-38. PubMed ID: 25138562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the androgen receptor (AR) with AR degradation enhancer ASC-J9® led to increase docetaxel sensitivity via suppressing the p21 expression.
    Luo J; Tian J; Chou F; Lin C; Xing EZ; Zuo L; Niu Y; Yeh S; Chang C
    Cancer Lett; 2019 Mar; 444():35-44. PubMed ID: 30248372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon inducible antiviral MxA is inversely associated with prostate cancer and regulates cell cycle, invasion and Docetaxel induced apoptosis.
    Brown SG; Knowell AE; Hunt A; Patel D; Bhosle S; Chaudhary J
    Prostate; 2015 Feb; 75(3):266-79. PubMed ID: 25327819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.